贝塔抑制剂在高血压左心室缩和心房的预防
Goran Koraćević1,2, Sladjana Mićić3, Milovan Stojanović4
1Department of Cardiovascular Diseases, University Clinical Center Niš, Serbia.
Current vascular pharmacology
|November 30, 2023
概括
贝塔抑制剂 (BBs) 可能有助于预防心房 (AF) 在患有高血压左心室缩 (HTN LVH) 的患者. 需要进一步的研究来证实它们与氨酸- ангиотензин- 阿尔多素系统 (RAAS) 阻断剂一起的抗心律失常作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 高血压左心室缩 (HTN LVH) 是发展心房动 (AF) 的重要危险因素.
- 心房动复杂化HTN LVH,导致心力衰竭与保存的喷射分数 (HFpEF),这带来了高死亡率.
研究的目的:
- 评估β-阻断剂 (BBs) 在预防AF方面的潜在益处.
- 评估BBs在与氨酸- ангиотензин- 阿尔多素系统 (RAAS) 阻断剂一起用于预防HTN LVH患者的AF时的作用.
主要方法:
- 在PubMed,Elsevier,SAGE,牛津和谷歌学者数据库中进行了全面的文献搜索.
- 搜索集中在2013年至2023年期间发表的研究中,使用与β阻塞剂,高血压和左心室缩相关的关键词.
- 采用了雪球搜索策略,审查了相关论文的参考文献及其引用文章.
主要成果:
- 高血压左心室缩 (HTN LVH) 已被确立为心房动 (AF) 的危险因素.
- β-阻断剂 (BBs) 以其抗心律不良的特性而闻名,通常被推用于降低高血压中AF发生率.
- 目前的指导方针建议BBs用于高血压的AF预防,但它们在HTN LVH患者的RAAS阻断剂上的特定抗失律作用需要进一步调查.
结论:
- 建议在高血压 (HTN) 中使用β-阻断剂 (BBs) 预防心房.
- 仅仅左心室缩 (LVH) 的回归并不完全代表抗高血压药物对AF的保护作用.
- 在HTN LVH患者中,BBs的抗失常疗效,特别是当与RAAS阻断剂结合使用时,需要进一步调查.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
342
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
473
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
473
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
839
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
839
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:28Antihypertensive Drugs: Types of β-Blockers
694
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
694
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
747
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
747